All In Biotech

Drug Trial Radar · NCT02641769

Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.

Intra-Testicular Transplantation of Purified Autologous None Marrow-Derived, Highly Specialized Cellular Populations, and Mesenchymal Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility. Patients Diagnosed With Any of the Following Might Benefit: Sertoli Cell Only Syndrome (SCOS), Maturation Arrest, Post- Chemotherapy, Small Testes, Cystic Fibrosis Obstructive Azoospermia, Post-hormonal Therapy,

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jan 2014

Primary completion

Jun 2030

Study completion Jan 2031

Sponsor

Lead sponsor
Stem Cells ArabiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 21 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous, bone marrow derived, highly specialized, differentiation specific into spermatogonial lineages, and mesenchymal stem cells injected into the seminiferous tubules and testis, through a 24-month follow-up period. The investigators' selected model of research is based on maximizing the efficiency of the approach by choosing an autologous pattern which preserves the genetic make-up of an individual that is vital in infertility conditions. Additionally, the approach involves injecting a combination of different but purified cell types which all aid in the re-establishment of spermatogenesis, and the generation of mature spermatozoa. Expected outcomes of this study are defined in general improvements in infertile patients with regards to testicular morphology, sexual function, semen quality, development of primary or secondary spermatocytes, spermatids, or mature spermatozoa in the testis, seminiferous tubules, or semen.

Conditions

  • Non-obstructive Azoospermia

Interventions

  • Stem Cell TransplantationBiological

    intervention with transplantation of autologous purified stem cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Appearance of spermatozoa in different maturation stages including primary spermatocytes, spermatids, and mature spermatozoa. Samples to be tested are either seminal fluid or testicular tissue obtained via fine needle aspiration (FNA) or surgical means.Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stem Cells of Arabia

    Amman, Amman Governorate, Jordan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.